Early endometrial cancer and endometrial atypical hyperplasia
Conditions
Interventions
Study of A1 group:Oral high progesterone
Study of A2 group:Intrauterine placed LNG-IUS
Study of B1 group:Segmental tylectomy under hysteroscope + consolidation therapy of highly active progesterone
Study of B2 group:Segmental tylectomy under hysteroscope + consolidation therapy of LNG-IUS
control group:Hysterosalpingo-oophorectomy
Sponsors
Women and Children Hospital of Northwest
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. Aged 40 years old or less, not producing or strong desire for fertility; 2. histologically confirmed is the IA stage (FIGO), high differentiation of endometrial adenocarcinoma; 3. the immunohistochemical female progesterone receptor positive; 4. except the ultrasound and MRI myometrium invasion or evidence of cervical involvement, no outside uterine lesions lymph nodes and distant metastasis; 5. Serum CA125 is normal and <35KU/L; 6. excluding cardiopulmonary dysfunction, acute injury of liver and kidney function, blood coagulation dysfunction, such as system disease, no taboo drug treatment; 7. merged to exclude hereditary colorectal polyps sex (ereditary non - polyposis colorectal cancer, HNPCC) family history, history of other tumors or combined with other parts of the tumor; 8. conditional close follow-up, good adherence, subjects were informed consent and voluntary access to the clinical trials.
Exclusion criteria
Exclusion criteria: 1. Complicated with cardiovascular, hepartic, renal and hematopoietic disease or other malignant tumor; 2. With poor compliance and difficult to follow-up; 3. Participating in other trials at the same time; 4. Other conditions improper for the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Treatment of working time;Complete response time;time to recurrence;remission rate;recurrence rate;Disease-free survival;The pregnancy rate after treatment to ease;expression quantity of PR-A;expression quantity of PR-B;expression quantity of PR-M;expression quantity of TRL4; | — |
Secondary
| Measure | Time frame |
|---|---|
| parturition rate; | — |
Countries
China
Contacts
Public ContactYanni Tian
The Northwest Women and Children Hospital
Outcome results
None listed